JP2023542295A - Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用 - Google Patents
Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用 Download PDFInfo
- Publication number
- JP2023542295A JP2023542295A JP2023516467A JP2023516467A JP2023542295A JP 2023542295 A JP2023542295 A JP 2023542295A JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023542295 A JP2023542295 A JP 2023542295A
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- linker
- antibody
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077983P | 2020-09-14 | 2020-09-14 | |
| US63/077,983 | 2020-09-14 | ||
| PCT/US2021/050337 WO2022056494A1 (en) | 2020-09-14 | 2021-09-14 | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542295A true JP2023542295A (ja) | 2023-10-06 |
| JP2023542295A5 JP2023542295A5 (https=) | 2024-09-20 |
Family
ID=78080567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516467A Pending JP2023542295A (ja) | 2020-09-14 | 2021-09-14 | Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12280124B2 (https=) |
| EP (1) | EP4210767A1 (https=) |
| JP (1) | JP2023542295A (https=) |
| KR (1) | KR20230070337A (https=) |
| CN (1) | CN116615251A (https=) |
| AU (1) | AU2021339892A1 (https=) |
| CA (1) | CA3191304A1 (https=) |
| CL (2) | CL2023000678A1 (https=) |
| CO (1) | CO2023004558A2 (https=) |
| IL (1) | IL301074A (https=) |
| MX (1) | MX2023002974A (https=) |
| WO (1) | WO2022056494A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3191304A1 (en) | 2020-09-14 | 2022-03-17 | Amy Han | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
| JP2025512735A (ja) | 2022-03-11 | 2025-04-22 | リジェネロン ファーマシューティカルズ，インク． | Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用 |
| WO2024027715A1 (en) * | 2022-08-01 | 2024-02-08 | Sciwind Biosciences Usa Co., Ltd | Anti-glp-1r antibodies and uses thereof |
| AU2024229138A1 (en) | 2023-02-27 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Liquid phase peptide support synthesis of peptides and peptidomimetics |
| US20250171516A1 (en) | 2023-11-03 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| TW202535467A (zh) * | 2023-12-29 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗體－多肽偶聯物及其醫藥用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011048614A2 (en) * | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
| JP5270687B2 (ja) * | 2007-12-11 | 2013-08-21 | カディラ ヘルスケア リミティド | グルカゴンアンタゴニスト活性及びｇｌｐ−１アゴニスト活性を有するペプチド模倣体 |
| GB2551945A (en) * | 2015-12-18 | 2018-01-10 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| US20180311372A1 (en) * | 2017-01-17 | 2018-11-01 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| FR2937972B1 (fr) | 2008-11-04 | 2013-03-29 | Galderma Res & Dev | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| SMT201700023T1 (it) | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| US9911931B2 (en) | 2014-06-26 | 2018-03-06 | Universal Display Corporation | Organic electroluminescent materials and devices |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| JP7702428B2 (ja) | 2020-05-12 | 2025-07-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法 |
| CA3191304A1 (en) | 2020-09-14 | 2022-03-17 | Amy Han | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
-
2021
- 2021-09-14 CA CA3191304A patent/CA3191304A1/en active Pending
- 2021-09-14 EP EP21787235.7A patent/EP4210767A1/en active Pending
- 2021-09-14 WO PCT/US2021/050337 patent/WO2022056494A1/en not_active Ceased
- 2021-09-14 IL IL301074A patent/IL301074A/en unknown
- 2021-09-14 KR KR1020237012710A patent/KR20230070337A/ko active Pending
- 2021-09-14 JP JP2023516467A patent/JP2023542295A/ja active Pending
- 2021-09-14 CN CN202180076678.6A patent/CN116615251A/zh active Pending
- 2021-09-14 AU AU2021339892A patent/AU2021339892A1/en active Pending
- 2021-09-14 US US17/475,248 patent/US12280124B2/en active Active
- 2021-09-14 MX MX2023002974A patent/MX2023002974A/es unknown
-
2023
- 2023-03-09 CL CL2023000678A patent/CL2023000678A1/es unknown
- 2023-04-12 CO CONC2023/0004558A patent/CO2023004558A2/es unknown
-
2025
- 2025-01-16 US US19/023,874 patent/US20250161476A1/en active Pending
- 2025-08-21 CL CL2025002511A patent/CL2025002511A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5270687B2 (ja) * | 2007-12-11 | 2013-08-21 | カディラ ヘルスケア リミティド | グルカゴンアンタゴニスト活性及びｇｌｐ−１アゴニスト活性を有するペプチド模倣体 |
| WO2011048614A2 (en) * | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
| GB2551945A (en) * | 2015-12-18 | 2018-01-10 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| US20180311372A1 (en) * | 2017-01-17 | 2018-11-01 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023002974A (es) | 2023-05-25 |
| AU2021339892A1 (en) | 2023-04-27 |
| IL301074A (en) | 2023-05-01 |
| CO2023004558A2 (es) | 2023-04-27 |
| CL2023000678A1 (es) | 2023-10-20 |
| CN116615251A (zh) | 2023-08-18 |
| AU2021339892A9 (en) | 2024-02-08 |
| US20250161476A1 (en) | 2025-05-22 |
| US12280124B2 (en) | 2025-04-22 |
| EP4210767A1 (en) | 2023-07-19 |
| WO2022056494A1 (en) | 2022-03-17 |
| KR20230070337A (ko) | 2023-05-22 |
| CA3191304A1 (en) | 2022-03-17 |
| US20220096648A1 (en) | 2022-03-31 |
| CL2025002511A1 (es) | 2025-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12280124B2 (en) | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | |
| US20220362396A1 (en) | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof | |
| AU2015280351B2 (en) | Fatty acids and their use in conjugation to biomolecules | |
| US20230330254A1 (en) | Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof | |
| JP2025131599A (ja) | 免疫グロブリン及びその使用 | |
| TW202102225A (zh) | 抗her2抗體-吡咯并苯二氮呯衍生物結合物 | |
| KR20240000510A (ko) | 소르틸린 활성 조절제 | |
| JP2024531480A (ja) | ステロイド化合物及びそのコンジュゲート | |
| JP2013503626A (ja) | グルカゴン受容体に対する抗体と、それらの使用 | |
| WO2023221975A1 (zh) | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 | |
| JP2022095624A (ja) | 代謝障害の治療に有用な化合物 | |
| WO2025096921A1 (en) | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof | |
| JP2025508927A (ja) | ソルチリン依存性疾患を治療するためのアミノ酸ベースのカルバメート及び／又は尿素 | |
| EP3455221B1 (en) | Dimeric compounds | |
| EA051876B1 (ru) | Конъюгаты антитело-лекарственное средство, содержащие пептидомиметики glp1, и их применения | |
| AU2024372425A1 (en) | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof | |
| IL325400A (en) | Anti-human CACNG1 antibody-drug conjugates and their uses | |
| WO2025085489A1 (en) | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof | |
| WO2025247309A1 (zh) | 融合蛋白分子及其应用 | |
| JP2026508282A (ja) | ペプチドおよびペプチド模倣体の液相ペプチド支持体合成 | |
| EA050796B1 (ru) | Иммуноглобулины и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240911 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260224 |